• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血浆循环肿瘤DNA的纵向监测可预测非霍奇金淋巴瘤患者的早期复发:病例系列

Longitudinal Monitoring of Plasma Circulating Tumour DNA Enables the Prediction of Early Relapse in Patients with Non-Hodgkin Lymphoma: A Case Series.

作者信息

Ji Hongyan, Long Xiaolu, Gu Jia, Jin Jin, Mao Xia, Wang Zhiqiong, Ma Heng, Chen Liting

机构信息

Department of Haematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.

FNA Cytology Examining Room, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.

出版信息

Diagnostics (Basel). 2021 Nov 5;11(11):2055. doi: 10.3390/diagnostics11112055.

DOI:10.3390/diagnostics11112055
PMID:34829401
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8618087/
Abstract

Growing evidence now suggests that circulating tumour DNA (ctDNA) has great potential as a non-invasive biomarker for disease monitoring, since ctDNA carries tumour-specific modifications. In particular, monitoring ctDNA has important implications for identifying patients with haematological malignancies at clinical risk of disease progression. We hereby describe three patients with B-cell non-Hodgkin lymphoma and investigate the clinical value of sequential ctDNA profiling for the early detection of tumour relapse. Somatic mutations in diagnostic tumour biopsy samples of these three patients were identified by applying high-throughput next-generation sequencing. Droplet digital PCR probes and primers were designed and tested for each hotspot mutation. Serial ctDNA analysis was subsequently conducted among these three patients. We found that the longitudinal monitoring of plasma ctDNA could predict for at least one month in advance compared with flow cytometry, cytology and conventional imaging modalities. Therefore, our results support liquid biopsy based on ctDNA as a non-invasive complementary modality to other detection methods for detecting early relapse and contribute to more precise management for non-Hodgkin lymphoma patients.

摘要

越来越多的证据表明,循环肿瘤DNA(ctDNA)作为一种用于疾病监测的非侵入性生物标志物具有巨大潜力,因为ctDNA携带肿瘤特异性修饰。特别是,监测ctDNA对于识别有疾病进展临床风险的血液系统恶性肿瘤患者具有重要意义。我们在此描述三名B细胞非霍奇金淋巴瘤患者,并研究连续ctDNA分析对于早期检测肿瘤复发的临床价值。通过应用高通量下一代测序确定了这三名患者诊断性肿瘤活检样本中的体细胞突变。针对每个热点突变设计并测试了液滴数字PCR探针和引物。随后对这三名患者进行了连续ctDNA分析。我们发现,与流式细胞术、细胞学和传统成像方式相比,血浆ctDNA的纵向监测可以提前至少一个月进行预测。因此,我们的结果支持基于ctDNA的液体活检作为一种非侵入性的补充方式,用于检测早期复发,并有助于对非霍奇金淋巴瘤患者进行更精确的管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5007/8618087/ef45d3093955/diagnostics-11-02055-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5007/8618087/718b363e47d5/diagnostics-11-02055-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5007/8618087/2c4583ffd831/diagnostics-11-02055-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5007/8618087/ef45d3093955/diagnostics-11-02055-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5007/8618087/718b363e47d5/diagnostics-11-02055-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5007/8618087/2c4583ffd831/diagnostics-11-02055-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5007/8618087/ef45d3093955/diagnostics-11-02055-g003.jpg

相似文献

1
Longitudinal Monitoring of Plasma Circulating Tumour DNA Enables the Prediction of Early Relapse in Patients with Non-Hodgkin Lymphoma: A Case Series.血浆循环肿瘤DNA的纵向监测可预测非霍奇金淋巴瘤患者的早期复发:病例系列
Diagnostics (Basel). 2021 Nov 5;11(11):2055. doi: 10.3390/diagnostics11112055.
2
Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.通过循环肿瘤 DNA 追踪未经治疗的中高危弥漫性大 B 细胞淋巴瘤的演变。
Br J Haematol. 2022 Feb;196(3):617-628. doi: 10.1111/bjh.17894. Epub 2021 Oct 19.
3
Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma.基于下一代测序技术检测淋巴瘤异基因干细胞移植后的循环肿瘤DNA
Br J Haematol. 2016 Dec;175(5):841-850. doi: 10.1111/bjh.14311. Epub 2016 Oct 6.
4
Circulating tumor DNA dynamically predicts response and/or relapse in patients with hematological malignancies.循环肿瘤DNA可动态预测血液系统恶性肿瘤患者的反应和/或复发情况。
Int J Hematol. 2018 Oct;108(4):402-410. doi: 10.1007/s12185-018-2487-2. Epub 2018 Jun 29.
5
Mutation profiling, tumour burden assessment, outcome prediction and disease monitoring by circulating tumour DNA in peripheral T-cell lymphoma.外周 T 细胞淋巴瘤中通过循环肿瘤 DNA 进行突变分析、肿瘤负担评估、预后预测和疾病监测。
Br J Haematol. 2023 Jul;202(1):86-95. doi: 10.1111/bjh.18824. Epub 2023 May 3.
6
Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma.循环肿瘤 DNA 的纵向监测可改善胃食管腺癌的预后和复发检测。
Br J Cancer. 2020 Oct;123(8):1271-1279. doi: 10.1038/s41416-020-1002-8. Epub 2020 Jul 28.
7
Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.对循环肿瘤 DNA 的纵向分析可用于跟踪胰腺癌中的肿瘤动态。
BMC Cancer. 2022 Apr 7;22(1):369. doi: 10.1186/s12885-022-09387-6.
8
Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.循环肿瘤 DNA 用于指导转移性乳腺癌临床试验入组和精准肿瘤学:一项队列研究。
PLoS Med. 2020 Oct 1;17(10):e1003363. doi: 10.1371/journal.pmed.1003363. eCollection 2020 Oct.
9
Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.治疗后残留 ctDNA 可预测早期非小细胞肺癌患者的早期复发。
Ann Oncol. 2022 May;33(5):500-510. doi: 10.1016/j.annonc.2022.02.007. Epub 2022 Mar 17.
10
Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment.嵌合抗原受体T细胞疗法后通过循环肿瘤DNA分析进行连续监测,以指导复发/难治性弥漫性大B细胞淋巴瘤的精准治疗。
J Cancer. 2021 Jul 13;12(18):5423-5431. doi: 10.7150/jca.60390. eCollection 2021.

引用本文的文献

1
Circulating Tumor DNA Combining with Imaging Analysis for Lesion Detection of Langerhans Cell Histiocytosis in Children.循环肿瘤DNA联合影像分析用于儿童朗格汉斯细胞组织细胞增多症病灶检测
Children (Basel). 2024 Nov 27;11(12):1449. doi: 10.3390/children11121449.
2
Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy.循环肿瘤 DNA 对预测接受一线治疗的弥漫性大 B 细胞淋巴瘤患者结局的临床意义。
BMC Med. 2022 Oct 25;20(1):369. doi: 10.1186/s12916-022-02562-3.

本文引用的文献

1
Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow up post CD19 CAR-T therapy.细胞质 CD79a 是 CD19 CAR-T 治疗后 B 淋巴母细胞白血病随访的有前途的生物标志物。
Leuk Lymphoma. 2022 Feb;63(2):426-434. doi: 10.1080/10428194.2021.1980214. Epub 2021 Oct 21.
2
Liquid biopsy in lymphoma: Molecular methods and clinical applications.淋巴瘤的液体活检:分子方法与临床应用。
Cancer Treat Rev. 2020 Dec;91:102106. doi: 10.1016/j.ctrv.2020.102106. Epub 2020 Sep 22.
3
Detection and Quantification of Chimeric Antigen Receptor Transgene Copy Number by Droplet Digital PCR versus Real-Time PCR.
通过液滴数字 PCR 与实时 PCR 检测和定量嵌合抗原受体转基因拷贝数。
J Mol Diagn. 2020 May;22(5):699-707. doi: 10.1016/j.jmoldx.2020.02.007.
4
The utility of non-invasive liquid biopsy for mutational analysis and minimal residual disease assessment in extramedullary multiple myeloma.非侵入性液体活检在髓外多发性骨髓瘤的突变分析和微小残留病评估中的应用
Br J Haematol. 2020 Apr;189(2):e45-e48. doi: 10.1111/bjh.16440. Epub 2020 Mar 19.
5
Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies.CAR19/22 T 细胞鸡尾酒疗法治疗难治/复发性 B 细胞恶性肿瘤患者的疗效和安全性。
Blood. 2020 Jan 2;135(1):17-27. doi: 10.1182/blood.2019000017.
6
Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic review.无细胞游离 DNA 作为弥漫性大 B 细胞淋巴瘤的生物标志物:一项系统评价。
Crit Rev Oncol Hematol. 2019 Jul;139:7-15. doi: 10.1016/j.critrevonc.2019.04.013. Epub 2019 Apr 27.
7
Application of Cell-free DNA Analysis to Cancer Treatment.游离DNA分析在癌症治疗中的应用。
N Engl J Med. 2018 Nov 1;379(18):1754-1765. doi: 10.1056/NEJMra1706174.
8
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.循环肿瘤 DNA 测量作为弥漫性大 B 细胞淋巴瘤的早期预后预测指标。
J Clin Oncol. 2018 Oct 1;36(28):2845-2853. doi: 10.1200/JCO.2018.78.5246. Epub 2018 Aug 20.
9
Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort.采用游离 DNA 高通量靶向测序对弥漫性大 B 细胞淋巴瘤进行无创监测:前瞻性队列分析。
Blood Cancer J. 2018 Aug 1;8(8):74. doi: 10.1038/s41408-018-0111-6.
10
Circulating tumor DNA dynamically predicts response and/or relapse in patients with hematological malignancies.循环肿瘤DNA可动态预测血液系统恶性肿瘤患者的反应和/或复发情况。
Int J Hematol. 2018 Oct;108(4):402-410. doi: 10.1007/s12185-018-2487-2. Epub 2018 Jun 29.